Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 13
Submit an article Journal homepage
257
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia – a prominent biomarker and potential target for anti-SLAMF7 antibody therapy

Ahmet H. ElmaagacliDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany; Correspondence[email protected]
,
Hans SalwenderDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany;
,
Christian JehnDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany;
,
Farouk DahmashDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany;
,
Anju SinghDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany;
,
Oliver WilsonDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany;
,
Marc PannenbeckersDepartment of Hematology/Oncology and Stem Cell Transplantation, Asklepios Klinik St.Georg, Hamburg, Germany;
,
Cornelius NiggemannDepartment of Pathology, Asklepios Klinik St. Georg, Hamburg, Germany
&
Mathias VierbuchenDepartment of Pathology, Asklepios Klinik St. Georg, Hamburg, Germany
 show all
Pages 3335-3338 | Received 15 Mar 2019, Accepted 19 May 2019, Published online: 04 Jun 2019

References

  • Tse E, Kwong Y-L. How I treat NK/T-cell lymphomas. Blood. 2013;121:4997–5005.
  • Tse E, Kwong Y-L. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10:85–97.
  • Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist. 2004;9:247–258.
  • Sun H, Wei S, Yang L. Dysfunction of immune system in the development of large granular lymphocyte leukemia. Hematology. 2019;24:139–147.
  • Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29:4410–4416.
  • Kwong Y-L, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129:2437–2442.
  • Chan JK, Tsang WY, Ng CS. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+. Blood. 1996;87:839–841.
  • Einsele H, Schrader M. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab. Ther Adv Hematol. 2016;715:299–301.
  • Hsi E, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784.
  • Tai Y, Dillon M, Song W, et al. Anti-CS1 umanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337.
  • Chen J, Zhong M-C, Guo H, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017;544:493–497.
  • Rethi B, Gogolak P, Szatman I, et al. SLAM/SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells. Blood. 2006;10:821–2829.
  • Kim JR, Horton NC, Mathew SO, et al. CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes. Inflamm Res. 2013;62:765–772.
  • Shi J, Bodo J, Zhao X, et al. SLAMF7 (CD219/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. Br J Haematol. 2018;185:145–147.
  • Nagy N, Cerboni C, Mattsson K, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer. 2000;88:439–447.
  • Ishii H, Takahara M, Nagato T, et al. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact dependent interaction through membrane-bound IL-15. Int J Cancer. 2012;130:48–58.
  • Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:917–927.
  • Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer fratricide of SLAMF + normal lymphocyte. Blood. 2017;130:2838–2847.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.